Abstract Characterization of the genetic landscape of Alzheimer’s disease (AD) and related
dementias (ADD) provides a unique opportunity for a better understanding of the associated …

Context Small single-center studies have shown that cerebrospinal fluid (CSF) biomarkers
may be useful to identify incipient Alzheimer disease (AD) in patients with mild cognitive …

Several concepts, which in the aggregate get might be used to account for “resilience”
against age‐ and disease‐related changes, have been the subject of much research. These …

Hyperphosphorylated tau protein (P-tau) in CSF is a core biomarker candidate of Alzheimer's
disease. Hyperphosphorylation of tau is thought to lead to neurofibrillary changes, a …

TREM 2 is an innate immune receptor expressed on the surface of microglia. Loss‐of‐function
mutations of TREM 2 are associated with increased risk of Alzheimer's disease ( AD ). …

Alzheimer's disease (AD) is a progressive age-related neurodegenerative disease. At the
time of clinical manifestation of dementia, significant irreversible brain damage is already …

Introduction Subjective cognitive decline (SCD) manifesting before clinical impairment
could serve as a target population for early intervention trials in Alzheimer's disease (AD). A …

The current study tested the accuracy of primary MRI and cerebrospinal fluid (CSF) biomarker
candidates and neuropsychological tests for predicting the conversion from mild cognitive …

Introduction There is a growing body of evidence that subtle deficits in instrumental activities
of daily living (IADL) may be present in mild cognitive impairment (MCI). However, it is not …

Cerebral small vessel disease (SVD) is common during ageing and can present as stroke,
cognitive decline, neurobehavioural symptoms, or functional impairment. SVD frequently …